Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2012
10/04/2012CA2831867A1 Therapeutic agent for cancer, and method for determining prognosis of cancer
10/04/2012CA2831848A1 Therapeutic treatment
10/04/2012CA2831713A1 Bifunctional hydroxy-bisphosphonic acid derivatives
10/04/2012CA2831710A1 Substituted benzimidazoles as mps-1 kinase inhibitors
10/04/2012CA2831612A1 Methods for treating cancer
10/04/2012CA2831590A1 (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
10/04/2012CA2831582A1 (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles , pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
10/04/2012CA2831562A1 Process for manufacturing conjugates of improved homogeneity
10/04/2012CA2831481A1 Compositions and methods for treating, diagnosing and monitoring disease
10/04/2012CA2831467A1 Preparation of maytansinoid antibody conjugates by a one-step process
10/04/2012CA2831454A1 Modulators of plexin b2 activity
10/04/2012CA2831426A1 Methods for increasing efficacy of folr1 cancer therapy
10/04/2012CA2831247A1 Cancer immunopotentiating agent containing rankl antagonist
10/04/2012CA2831143A1 Cyclopropylamines as lsd1 inhibitors
10/04/2012CA2831015A1 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof
10/04/2012CA2830984A1 Inhibitors of 17.beta.-hsd1, 17.beta.-hsd3 and 17.beta.-hsd10
10/04/2012CA2830822A1 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
10/04/2012CA2830806A1 Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
10/04/2012CA2830442A1 Antibodies directed against icos and uses thereof
10/04/2012CA2830430A1 Antitumor agent comprising carbon dioxide as an active ingredient
10/04/2012CA2830338A1 Antibody-drug conjugates
10/04/2012CA2830148A1 Novel furanone derivatives
10/04/2012CA2829241A1 Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics
10/04/2012CA2829105A1 Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
10/04/2012CA2828700A1 Pharmaceutical composition containing block copolymer comprising boronic acid compound
10/04/2012CA2827455A1 Process for the production of a pemetrexed salt
10/04/2012CA2827214A1 Lipoxygenase inhibitors
10/04/2012CA2822177A1 Nanoparticles loaded with chemotherapeutic antitumoral drug
10/03/2012EP2505645A1 MicroRNA as a cancer progression predictor and its use for treating cancer
10/03/2012EP2505589A1 Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof
10/03/2012EP2505587A1 Method for manufacturing a 6-substituted-1-methyl-1h-benzimidazole derivative, and manufacturing intermediate from said method
10/03/2012EP2505209A1 Fcgamma-RIIB-specific antibodies and methods of the use thereof
10/03/2012EP2505205A1 Anti-PDGFR Alpha Antibodies
10/03/2012EP2505204A2 Method of treating prostate cancer with the GnRH antagonist degarelix
10/03/2012EP2505198A1 Compounds for use as therapeutic agents affecting p53 expression and/or activity
10/03/2012EP2504452A1 Materials and methods useful for affecting tumor cell growth, migration and invasion
10/03/2012EP2504363A1 Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
10/03/2012EP2504341A1 A new crystalline form of pemetrexed disodium
10/03/2012EP2504339A1 Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
10/03/2012EP2504338A1 Pyridine-pyridinone derivatives, preparation and therapeutic use thereof
10/03/2012EP2504336A1 Novel naphthyridine derivatives and the use thereof as kinase inhibitors
10/03/2012EP2504332A1 An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
10/03/2012EP2504331A1 Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
10/03/2012EP2504324A1 Sultam derivatives
10/03/2012EP2504314A1 Quinazoline derivatives
10/03/2012EP2504035A2 Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
10/03/2012EP2504032A2 Antagonists of il-6 to prevent or treat thrombosis
10/03/2012EP2504031A2 Antibodies to il-6 and use thereof
10/03/2012EP2504030A2 Antagonists of il-6 to raise albumin and/or lower crp
10/03/2012EP2504022A1 Brain tumor targeting peptides and methods
10/03/2012EP2504014A1 Modulation of epidermal growth factor receptor ligands
10/03/2012CN1993318B Bis(thio-hydrazide amide) salts for treatment of cancers
10/03/2012CN102712934A Recombinant adenovirus having anti-angiogenesis activity
10/03/2012CN102712697A Vault complexes for cytokine delivery
10/03/2012CN102712658A N-containing heteroaryl derivatives as jak3 kinase inhibitors
10/03/2012CN102712656A 2,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors
10/03/2012CN102712653A Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof
10/03/2012CN102712650A Spiro-oxindole MDM2 antagonists
10/03/2012CN102712648A Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
10/03/2012CN102712646A RAF inhibitor compounds and methods of use thereof
10/03/2012CN102712645A Compounds
10/03/2012CN102712642A N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
10/03/2012CN102712641A MK2 inhibitors
10/03/2012CN102712635A 1h-pyrazolo [3,4-b] pyridine compounds for inhibiting RAF kinase
10/03/2012CN102712629A An amorphous and a crystalline form of Genz 112638 hemitartrat as inhibitor of glucosylceramide synthase
10/03/2012CN102712604A Sulfoxide derivatives for treating tumors
10/03/2012CN102712601A A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
10/03/2012CN102712591A Fluorinated derivatives of 3-hydroxypyridin-4-ones
10/03/2012CN102712575A Homoglutamic acid derivatives
10/03/2012CN102711841A Iodine-labeled homoglutamic acid and glutamic acid derivatives
10/03/2012CN102711837A Salt form of a multi-arm polymer-drug conjugate
10/03/2012CN102711836A Acid salt forms of polymer-drug conjugates and alkoxylation methods
10/03/2012CN102711825A Dosage regimen for administering an EpCAMxCD3 bispecific antibody
10/03/2012CN102711824A Vaccines directed to Langerhans cells
10/03/2012CN102711792A Polypeptide or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis of cancer cells
10/03/2012CN102711788A Targeted delivery using tissue-specific peptidomimetic ligands
10/03/2012CN102711781A A novel boswellia low polar gum resin extract and its synergistic compositions
10/03/2012CN102711779A Composition containing black ginseng extracts for preventing or treating liver cancer
10/03/2012CN102711772A Anti-neoplastic uses of artemin antagonists
10/03/2012CN102711766A N-9-substituted purine compounds, compositions and methods of use
10/03/2012CN102711756A Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
10/03/2012CN102711755A Pharmaceutical composition for peroral administration of 3,3'-diindolylmethane
10/03/2012CN102703489A Construction method for prokaryotic secretory expression vector of protein transduction domain-Apoptin (PTD-Apoptin) fusion protein and application of prokaryotic secretory expression vector
10/03/2012CN102703456A Action target site of death-associated protein kinase (DAPK3) gene hsa-miR-20a
10/03/2012CN102703452A siRNA double-strand for inhibiting Bcl2 gene expression and application thereof
10/03/2012CN102703447A Oligonucleotide with breast cancer treatment effect
10/03/2012CN102703393A Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
10/03/2012CN102703389A Poxviral oncolytic vectors
10/03/2012CN102703379A Human liver progenitors
10/03/2012CN102703327A Cladosporium Sp. XJ-AC03 and application thereof
10/03/2012CN102703060A Targeted tracing noble metal fluorescence probe and anti-tumor prodrug
10/03/2012CN102702454A PH response four-arm star block copolymer and preparation method and application thereof
10/03/2012CN102702453A pH-responsive 6-arm star block copolymer and preparation method and application thereof
10/03/2012CN102702376A Process for extracting chestnut polysaccharide by pressurized solvent extraction method
10/03/2012CN102702375A Method for extracting polysaccharide from processed residua of taxus chinensis
10/03/2012CN102702358A Antibody against the CSF-1 R
10/03/2012CN102702353A Anti-glypican 3 antibody
10/03/2012CN102702319A HLA-A*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
10/03/2012CN102702302A Tanshinone class I derivant and synthesizing method and application thereof
10/03/2012CN102702298A Glycyrrhetinic acid derivative and preparation method and medical application thereof
1 ... 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 ... 2211